The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Mergers & AcquisitionsMedium•8 May 2026•

1 min read

Assertio and Garda Therapeutics Mutually Agree to Delay Tender Offer Until May 2026

Key Facts

1Assertio and Garda Therapeutics mutually agreed to delay the launch of the tender offer to acquire all outstanding shares until May 14, 2026.

2The acquisition price is set at $21.80 per share under the amended and restated merger agreement.

Assertio Holdings and Garda Therapeutics have mutually agreed to postpone the commencement of their tender offer to acquire all outstanding shares until May 14, 2026. Under the terms of the amended and restated merger agreement, the acquisition price remains fixed at $21.80 per share. This strategic delay modifies the previously announced timeline for the merger between the two pharmaceutical entities. While a prolonged timeline typically introduces market uncertainty, the maintained offer price provides a definitive valuation anchor for shareholders. Investors are closely monitoring the impact of this extension on ASRT stock performance. The decision reflects a coordinated effort to navigate the merger process over a longer horizon, ensuring all contractual conditions are met.